Adipocyte-Targeting Gene Delivery Complex for Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene delivery systems face challenges in efficiently targeting adipocytes for obesity treatment due to cytotoxicity, low transfection efficiency, and immune reactions, particularly for mature obese adipocytes, where existing methods achieve only about 10% transfection efficiency and lack effective adipose tissue-selective targeting.
Innovation Solution
A non-viral adipocyte-targeting gene delivery complex using a dual plasmid vector with an adipocyte-targeting sequence and a nine-arginine (R9) peptide, specifically inhibiting the expression of FABP4 and FABP5 genes, represented by SEQ ID NO: 1, to achieve simultaneous inhibition and reduce cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene delivery, then transfection efficiency is improved, but immunogenicity and genetic recombination problems occur
Solution Approach 1:
The patent uses non-viral polymeric vectors instead of viral vectors, employing disposable, non-living polymer carriers that avoid immunogenicity while maintaining gene delivery functionality. The polymeric vectors are designed to be transient and non-integrating, eliminating long-term safety concerns.
Solution Approach 2:
The patent introduces polymeric vectors as intermediary carriers between the gene payload and target cells. These polymers serve as mediators that facilitate gene delivery without the harmful properties of viral vectors, using biocompatible materials like PEI or chitosan to bridge the gap between DNA and cellular uptake mechanisms.
2Stability of the object's composition
If polymeric gene delivery systems are used, then stability is improved, but intracellular trafficking barriers occur
Solution Approach 1:
The patent optimizes polymeric vector parameters including molecular weight, charge density, and structural configuration to enhance intracellular trafficking. By adjusting these parameters, the polymers can effectively escape endosomes and deliver genes to the nucleus while maintaining stability in physiological conditions.
Solution Approach 2:
The patent employs composite polymeric structures combining multiple functional components within a single vector system. These composite materials integrate gene-binding capabilities, cell-penetrating properties, and endosome-escaping functionality, simplifying the overall delivery process while maintaining stability.
3Reliability
If synthetic peptides are used for gene delivery, then endosomal escape is improved, but toxicity and serum instability occur
Solution Approach 1:
The patent combines synthetic peptides with polymeric vectors to create composite delivery systems. The peptides provide endosomal escape functionality while the polymers serve as the main structural carrier, reducing overall toxicity. This composite approach allows the system to benefit from both components without their individual drawbacks.
Solution Approach 2:
The patent applies synthetic peptide functionality locally at specific regions of the polymeric vector rather than using peptides throughout the entire system. This localized application provides endosomal escape capability where needed while minimizing the amount of potentially toxic peptide material present in the overall delivery system.
4Adaptability or versatility
If short cationic peptides are used, then cell-specific delivery is improved, but DNA stability and complex stability are insufficient
Solution Approach 1:
The patent merges short cationic peptides with polymeric vectors to create a unified delivery system. The polymer provides structural stability and DNA protection, while the attached or associated peptides provide cell-specific targeting and delivery enhancement. This combination achieves both stability and adaptability simultaneously.
Solution Approach 2:
The patent incorporates cell-specific peptide sequences into the polymeric vector structure in advance, before delivery to target cells. This preliminary integration ensures that the complex maintains stability during circulation while being pre-equipped with the necessary targeting capabilities for efficient cell-specific delivery upon reaching the destination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complex effectively delivers therapeutic genes to adipocytes, achieving superior therapeutic effects on obesity with reduced inflammation and body weight loss without cytotoxicity, as demonstrated by the reduction in FABP4 and FABP5 mRNA levels and body weight loss in animal models.
Implementation Method 1
synthetic peptide-based gene delivery systems cause leakage in endosomal membranes at low pH, and thus lead to DNA condensation, and also promote endosomal escape
Implementation Method 2
a complex of an adipocyte-targeting sequence (ATS) and a specific peptide sequence binds to prohibitin which is expressed in a mature adipocyte, and thus effectively delivers a gene into the adipocyte
Implementation Method 3
the gene for treatment of obesity and obesity-induced metabolic syndromes is a base sequence inhibiting expression of a FABP4 gene and a FABP5 gene
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The present disclosure relates to: an adipocyte-targeting non-viral gene delivery complex comprising a sh(FABP4 + FABP5) dual plasmid vector; and treatment for obesity and obesity-induced metabolic syndromes by using the same and, more particularly, to a gene delivery complex comprising: an adipocyte-targeting sequence; a nine-arginine (R9) peptide; and a dual plasmid vector comprising a gene for treatment of obesity and obesity-induced metabolic syndromes, wherein the gene for treatment of obesity and obesity-induced metabolic syndromes is a base sequence inhibiting the expression of a FABP4 gene and a FABP5 gene. According to the present disclosure, in order to treat obesity-related diseases, a dual plasmid vector capable of simultaneously inhibiting the FABP4 and FABP5 genes is produced, and this vector is bound to a predetermined delivery system that specifically delivers the vector into adipocytes so as to provide a gene delivery complex. In this way, it is possible to achieve an excellent therapeutic effect on obesity which targets only adipocytes without cytotoxicity.